摘要
目的探讨瘦素受体(OBR)和磷酸化蛋白激酶B(p-AKT)在弥漫大B细胞淋巴瘤(DLBCL)中的表达及其意义。方法应用免疫组织化学法检测山东第一医科大学附属省立医院2010年至2015年90例DLBCL和20例反应性淋巴组织增生(RLH)组织中OBR和p-AKT的表达;应用细胞增殖实验(MTS)检测瘦素对DLBCL细胞株SUDHL4和SUDHL5增殖能力的影响;应用蛋白质印迹法检测瘦素培养后SUDHL4和SUDHL5细胞p-AKT的表达情况。结果OBR和p-AKT在DLBCL中的高表达率为47.7%(43/90)、27.7%(25/90),在20例RLH中均为低表达,OBR和p-AKT在DLBCL和RLH中的表达差异均有统计学意义(P<0.01,P=0.027)。OBR和p-AKT的表达与患者年龄、性别、结外浸润、临床分期、乳酸脱氢酶(LDH)水平、B症状及国际预后指数(IPI)评分均无关(均P>0.05)。OBR和p-AKT在DLBCL中的表达呈正相关(r=0.532,P<0.05)。瘦素可以提高SUDHL4和SUDHL5细胞增殖能力,促进细胞内p-AKT的表达。结论瘦素和OBR可通过激活PI3K-AKT途径促进DLBCL细胞的增殖,参与DLBCL的发生发展。
Objective To investigate the expressions of leptin receptor(OBR)and phosphorylated protein kinase B(p-AKT)in patients with diffuse large B-cell lymphoma(DLBCL)and its significance.Methods Immunohistochemistry was applied to detect the expressions of OBR and p-AKT in tissues from 90 patients with DLBCL and 20 patients with reactive lymphoid hyperplasia(RLH)between 2010 and 2015 in Shandong Provincial Hospital Affiliated to Shandong First Medical University.Cell proliferation assay was used to detect the effect of leptin on the proliferation of SUDHL4 and SUDHL5 in DLBCL cell lines,and the expression of p-AKT in SUDHL4 and SUDHL5 after the cultured leptin was detected by using Western blot.Results The high expression rate of OBR and p-AKT of DLBCL was 47.7%(43/90)and 27.7%(25/90),respectively,and low expression was found in 20 cases of RLH.There were statistically differences in the expressions of OBR and p-AKT in DLBCL and RLH(P<0.01,P=0.027).The expressions of OBR and p-AKT were not correlated with age,gender,extranodal infiltrations,clinical staging,lactic dehydrogenase(LDH)level,B-symptom and international prognostic index(IPI)score(all P>0.05).The expression of OBR was positively related with that of p-AKT in DLBCL patients(r=0.532,P<0.05).Leptin could increase the proliferation of SUDHL4 and SUDHL5 cells and promote the expression of p-AKT.Conclusion Leptin and OBR can promote the proliferation of DLBCL cells and may be involved in the occurrence and development of DLBCL by activating PI3K-AKT pathway.
作者
宋琳
吕蓓蓓
侯东省
张亚洲
Song Lin;Lyu Beibei;Hou Dongsheng;Zhang Yazhou(Department of Pathology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China)
出处
《白血病．淋巴瘤》
CAS
2020年第6期331-334,共4页
Journal of Leukemia & Lymphoma
